Enspryng Shows Strong Relapse Reduction in Rare Neurological Disorder

Roche has announced positive results from the Phase III METEOROID trial evaluating Enspryng (satralizumab) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare condition affecting the central nervous system.

The randomised, placebo-controlled study met its primary endpoint, with the therapy reducing the risk of relapse by 68%. After 48 weeks, 87% of patients receiving Enspryng remained relapse-free compared to 67% in the placebo group, with benefits observed as early as eight weeks.

The treatment also lowered annual relapse rates, reduced inflammation, and decreased the need for rescue therapies such as steroids and immunoglobulins. Additional findings included fewer MRI-detected lesions and reduced hospitalisation rates.

Enspryng was well tolerated, with a safety profile consistent with previous studies. These findings highlight its potential as a targeted therapy for this rare autoimmune neurological condition.

22-04-2026